The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version of ...

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, which brought in ...

Late last year we reported on the United States Court of Appeals for the Federal Circuit decision holding that certain device patents should not ...

The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...

IPA also stated that while generics are priced lower than the corresponding brands, it is unfair and unacceptable to link quality with cost.

IPA also refuted the study's reliance on the FDA Adverse Event Reporting System (FAERS) data, stating that FAERS data is ...

A much-anticipated meeting between President Donald Trump and representatives of the pharmaceutical industry took place ...

Asserting that quality standards are not region-dependent, the Indian Pharmaceutical Alliance (IPA) on Wednesday refuted the ...

VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 ...

The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality ...

Catalyst Pharmaceuticals' Firdapse delivers strong growth with a 37% CAGR. Click here to find out why CPRX stock is a Hold.